DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
| Status: | Recruiting |
|---|---|
| Conditions: | Gastrointestinal, Hepatitis |
| Therapuetic Areas: | Gastroenterology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2018 |
| Start Date: | November 21, 2017 |
| End Date: | September 1, 2020 |
| Contact: | Raymond Chung, MD |
| Email: | RChung@partners.org |
| Phone: | 617-724-7562 |
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Liver Transplant
This is a single center study for the donation of HCV-positive livers to HCV negative
recipient patients, with preemptive, interventional treatment to prevent HCV transmission
upon transplantation.
recipient patients, with preemptive, interventional treatment to prevent HCV transmission
upon transplantation.
Patients will be selected based on diminished likelihood of receiving a liver from the
waitlist within a period during which they would be likely to succumb to severe
comorbidities. This will be determined in part through use of a patient's MELD score, listing
status, and clinical judgment. To ensure maximal benefit for the recipient, only high quality
donor livers will be accepted.
waitlist within a period during which they would be likely to succumb to severe
comorbidities. This will be determined in part through use of a patient's MELD score, listing
status, and clinical judgment. To ensure maximal benefit for the recipient, only high quality
donor livers will be accepted.
Inclusion Criteria:
- Recipient is Age ≥ 18 years
- Met MGH transplant center criteria, listed for liver transplant
- HCV naïve
- Able to sign informed consent
Exclusion Criteria:
- Pregnant or nursing (lactating) women
- HIV positivity
- Need for dual organ transplant
- Any contra-indication to liver transplantation per center protocol
We found this trial at
1
site
Click here to add this to my saved trials
